PRINT: ISSN 2221-1896
ONLINE : ISSN 2223-0343

Role of proteasome-ubiquitination degradation pathway in animal cancer - an insight

Supriya Shiwani, Sung Jin Lee and Naresh Kumar Singh*

Deptartment of Animal Biotechnology, College of Animal Life Sciences, Kangwon National University, Republic of Korea


Most intracellular proteins are degraded by the proteasome, a multicatalytic enzyme complex containing a 20S catalytic core and two 19S regulatory complexes. The proteasome is responsible for the degradation of intracellular proteins that are particularly involved in cell cycle control and the regulation of apoptosis. Preclinical studies have in the past used various forms of proteosome inhibitors such as chemical (Bortezomib), natural resources (marine microbial metabolites, green tea polyphenols, flavonoids etc.) and metal complexes. Such proteosome inhibitors have been observed to decrease proliferation, induce apoptosis, and enhance the activity of chemotherapy and radiation, and reverses chemoresistance in a variety of hematologic and solid malignancies. However, their clinical significance and relevance of targeting the tumor survival-associated proteasome pathway for cancer treatment, intervention and prevention needs to be discussed. We therefore, reviewed here how the structure and function of the proteasome deals with various forms of proteasome inhibitors that counteract cancer propagation in animals.

Keywords: Proteasome, p53; Ubiquitin; neoplasm; cancer
To cite this article: Shiwani S, SJ Lee and NK Singh, 2014. Role of proteasome-ubiquitination degradation pathway in animal cancer - An insight. Res. Opin. Anim. Vet. Sci., 4(5): 224-232.

Home  |  Archive  |  Instructions  |  Submission  |  Editorial Board  |  Sample Paper

All rights reserved ©